TSHA · Taysha Gene Therapies, Inc.
$5.95
-0.04 (-0.67%)
At close · Aug 14
Market Cap
$1.94B
Shares
325.83M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Sean Nolan | Chief Executive Officer and Director | $4,099,065 |
| Kamran Alam | Chief Financial Officer | $2,146,964 |
| Sukumar Nagendran | President and Head of Research and Development and Director | $2,092,890 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Sean Nolan | Chief Executive Officer and Director | $4,727,861 |
| Sukumar Nagendran | President and Head of Research and Development | $3,601,660 |
| Kamran Alam | Chief Financial Officer | $2,518,777 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Sean Nolan | Chief Executive Officer and Director | $1,522,515 |
| Sukumar Nagendran | President and Head of Research and Development | $1,248,120 |
| Kamran Alam | Chief Financial Officer | $975,401 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Sean Nolan | Chief Executive Officer and Director | $1,899,276 |
| Sukumar Nagendran | President and Head of Research and Development | $1,363,545 |
| Kamran Alam | Chief Financial Officer | $1,201,823 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kathleen Reape | director | Resigned | 2023-11-01 |
| Sean Stalfort | director | Appointed | 2023-06-22 |
| Kathleen Reape | Class III director | Resigned | 2023-04-27 |
| Sukumar Nagendran | President and Head of Research and Development | Appointed | 2022-12-22 |
| Sean Nolan | Chief Executive Officer | Appointed | 2022-12-22 |
| RA Session II | President and Chief Executive Officer | Resigned | 2022-12-22 |
Key facts
CIK
1806310
CUSIP
877619106
13F (30d)
207 filings
201 filers
Visit website
Investor relations